中华流行病学杂志
中華流行病學雜誌
중화류행병학잡지
CHINESE JOURNAL OF EPIDEMIOLOGY
2010年
9期
1013-1016
,共4页
刘佳%崔为国%孙国清%朱新朋%田随安%孙定勇%杨文杰%李宁%朱谦%王哲
劉佳%崔為國%孫國清%硃新朋%田隨安%孫定勇%楊文傑%李寧%硃謙%王哲
류가%최위국%손국청%주신붕%전수안%손정용%양문걸%리저%주겸%왕철
艾滋病%治疗%CD4+淋巴细胞%HIV病毒载量
艾滋病%治療%CD4+淋巴細胞%HIV病毒載量
애자병%치료%CD4+림파세포%HIV병독재량
AIDS%Therapy%CD4+T cells%HIV virus load
目的 为评估和预测河南省艾滋病抗病毒治疗状况,分析患者CD4+T淋巴细胞和病毒载量.方法 通过"河南省艾滋病检测实验室网络数据库"收集河南省艾滋病人群2009年CD4+T淋巴细胞计数和病毒载量检测结果及相关信息.对其中未治疗和2005-2008年加入一线抗病毒治疗人群(＞13岁)的检测结果构成比进行横断面研究.结果 在2009年上、下半年河南省未治疗的艾滋病人群中,CD4+T淋巴细胞检测＜200个/μl者均＞20%(χ2=2.059,P=0.151),200～350个/μl者的构成比则由上半年27.61%上升到下半年的29.41%(χ2=4.636,P=0.031),＞350个/μl者的构成比从上半年51.49%下降到下半年的48.60%(χ2=9.767,P=0.002).在未治疗的艾滋病人群中,病毒载量＞10 000 copy/ml和＞30 000 copy/ml者所占百分比分别为34.53%和19.65%.2005-2008年间加入一线抗病毒治疗的艾滋病人群中,治疗时间越长,CD4+T淋巴细胞＞350个/μl者的构成比越高(χ2=148.689,P＜0.001),＜200个/μl者的构成比则越低(χ2=46.686,P＜0.001);同时,病毒载量＜500 copy/ml者的构成比越低(χ2=9.066,P=0.003),＞10 000 copy/ml者的构成比则越高(χ2=6.597,P=0.010).结论 河南省多年来进行的艾滋病一线抗病毒治疗疗效显著,但随着治疗时间的增加,治疗失败的风险也逐渐加大,应及时进行耐药监测,更换治疗方案.同时应加强未治疗人群的检测,加大抗病毒治疗的投入并扩大纳入治疗的范围.
目的 為評估和預測河南省艾滋病抗病毒治療狀況,分析患者CD4+T淋巴細胞和病毒載量.方法 通過"河南省艾滋病檢測實驗室網絡數據庫"收集河南省艾滋病人群2009年CD4+T淋巴細胞計數和病毒載量檢測結果及相關信息.對其中未治療和2005-2008年加入一線抗病毒治療人群(＞13歲)的檢測結果構成比進行橫斷麵研究.結果 在2009年上、下半年河南省未治療的艾滋病人群中,CD4+T淋巴細胞檢測＜200箇/μl者均＞20%(χ2=2.059,P=0.151),200～350箇/μl者的構成比則由上半年27.61%上升到下半年的29.41%(χ2=4.636,P=0.031),＞350箇/μl者的構成比從上半年51.49%下降到下半年的48.60%(χ2=9.767,P=0.002).在未治療的艾滋病人群中,病毒載量＞10 000 copy/ml和＞30 000 copy/ml者所佔百分比分彆為34.53%和19.65%.2005-2008年間加入一線抗病毒治療的艾滋病人群中,治療時間越長,CD4+T淋巴細胞＞350箇/μl者的構成比越高(χ2=148.689,P＜0.001),＜200箇/μl者的構成比則越低(χ2=46.686,P＜0.001);同時,病毒載量＜500 copy/ml者的構成比越低(χ2=9.066,P=0.003),＞10 000 copy/ml者的構成比則越高(χ2=6.597,P=0.010).結論 河南省多年來進行的艾滋病一線抗病毒治療療效顯著,但隨著治療時間的增加,治療失敗的風險也逐漸加大,應及時進行耐藥鑑測,更換治療方案.同時應加彊未治療人群的檢測,加大抗病毒治療的投入併擴大納入治療的範圍.
목적 위평고화예측하남성애자병항병독치료상황,분석환자CD4+T림파세포화병독재량.방법 통과"하남성애자병검측실험실망락수거고"수집하남성애자병인군2009년CD4+T림파세포계수화병독재량검측결과급상관신식.대기중미치료화2005-2008년가입일선항병독치료인군(＞13세)적검측결과구성비진행횡단면연구.결과 재2009년상、하반년하남성미치료적애자병인군중,CD4+T림파세포검측＜200개/μl자균＞20%(χ2=2.059,P=0.151),200～350개/μl자적구성비칙유상반년27.61%상승도하반년적29.41%(χ2=4.636,P=0.031),＞350개/μl자적구성비종상반년51.49%하강도하반년적48.60%(χ2=9.767,P=0.002).재미치료적애자병인군중,병독재량＞10 000 copy/ml화＞30 000 copy/ml자소점백분비분별위34.53%화19.65%.2005-2008년간가입일선항병독치료적애자병인군중,치료시간월장,CD4+T림파세포＞350개/μl자적구성비월고(χ2=148.689,P＜0.001),＜200개/μl자적구성비칙월저(χ2=46.686,P＜0.001);동시,병독재량＜500 copy/ml자적구성비월저(χ2=9.066,P=0.003),＞10 000 copy/ml자적구성비칙월고(χ2=6.597,P=0.010).결론 하남성다년래진행적애자병일선항병독치료료효현저,단수착치료시간적증가,치료실패적풍험야축점가대,응급시진행내약감측,경환치료방안.동시응가강미치료인군적검측,가대항병독치료적투입병확대납입치료적범위.
Objective To analyze the CD4 +T cells and virus load in HIV/AIDS affected population and to evaluate the HIV/AIDS antiretroviral therapy programs in Henan province.Methods "Henan HIV/AIDS Testing Laboratory Network Database" was used to collect the data on CD4+ T cells and virus load (VL) value and corresponding information in HIV/AIDS population of Henan in 2009. Cross-sectional studies was used to study the constituent ratio of CD4 + T cells and virus load value in individuals who had not received antiretroviral-treated (ART) and had joined first-line ART between the year of 2005 to 2008 among HIV/AIDS population of Henan. Results As to these people living with HIV/AIDS that had not received ART in the first half and the second half year of 2009, the constituent ratio of individuals whose CD4+T cells were less than 200 cells/μl both accounted for more than 20% (χ2=2.059, P=0.151). The constituent ratio of individuals whose CD4+T cells were in 200-350 cells/μl and more than 350 cells/μl increased from 27.61% to 29.41%(χ2=4.636, P=0.031 ) and decreased from 51.49% to 48.60% (χ2=9.767, P=0.002), respectively.Meanwhile, we saw 34.53% and 19.65% of the patients whose virus load was ＞10 000 copy/mland ＞30 000 copy/ml in this population. Patients that joined first-line ART during 2005-2008 showed the following results: the longer of the therapy time, the higher constituent ratio of individuals whose CD4+ T cells were more than 350 cells/μl (χ2= 148.689, P＜0.001) and the lower constituent ratio of individuals of whose CD4+T cells were less than 200 cells/μl (χ2=46.686,P＜0.001).Simultaneously, the lower constituent ratio of individuals whose viral load was less than 500 copy/ml (χ2=9.066, P=0.003) and the higher constituent ratio of individuals whose virus load was more than 10 000 copy/ml (χ2=6.597, P=0.010). Conclusion Significant curative effect had been achieved in AIDS first-line ART of Henan, but along with the increasing treatment time, the risk of treatment failure also increased. Drug resistance test and changing of treatment protocols were needed. To reach better and more efficient effects on therapy, factors as more detections and investments on ART, expanding the scope of treatment etc. were needed on those people living with HIV/AIDS that had not received ART.
